<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664764</url>
  </required_header>
  <id_info>
    <org_study_id>Basal insulin toddlers</org_study_id>
    <nct_id>NCT04664764</nct_id>
  </id_info>
  <brief_title>Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.</brief_title>
  <official_title>The Effect of Long- and Intermediate-acting Insulins on Glycemic Control and Risk of Hypoglycemia Among Toddlers and Preschool Children With Newly Onset Type 1 Diabetes Mellitus: A Randomized Three Armed Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Achieving glycemic control without risking hypoglycemia imposes a major challenge&#xD;
      in the management of toddlers and preschool children with Type 1 diabetes(T1D). Optimal&#xD;
      insulin therapy for young children with T1D should provide effective glycemic control while&#xD;
      minimizing the risk of hypoglycemia and hyperglycemia. Despite the advantages of the&#xD;
      basal-bolus insulin regimens, hypoglycemia still presents a major barrier in achieving&#xD;
      desirable glycemic control. Objectives: To compare the effectiveness of insulin degludec to&#xD;
      insulin glargine and NPH in toddlers and preschool children with T1D in terms of glycosylated&#xD;
      hemoglobin(HbA1C) and frequency of hypoglycemic episodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">March 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the effectiveness of insulin degludec to insulin glargine and NPH</measure>
    <time_frame>6 months</time_frame>
    <description>to compare the effectiveness of insulin degludec in the form of HBA1C and frequency of hypoglycemia to insulin glargine and NPH in toddlers and preschool children with T1D in terms of HbA1C, IDD and frequency of hypoglycemic episodes.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes Mellitus With Hypoglycemia</condition>
  <condition>type1diabetes</condition>
  <arm_group>
    <arm_group_label>degludec arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A received insulin degludec,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glargine arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group B received insulin glargine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C received NPH insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degludec</intervention_name>
    <description>Basal insulin comparison</description>
    <arm_group_label>degludec arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>Basal insulin comparison</description>
    <arm_group_label>glargine arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>Basal insulin comparison</description>
    <arm_group_label>NPH group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Toddlers and preschool children with T1D on insulin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with other medical conditions (i.e. celiac disease or autoimmune&#xD;
             thyroiditis), patients with other types of diabetes mellitus (i.e. maturity onset&#xD;
             diabetes of youth (MODY) and type 2 diabetes mellitus), patients with history of liver&#xD;
             disease or any disorder likely to impair liver functions or elevated liver enzymes,&#xD;
             renal impairment due to cause other than diabetes, hypertension, patients taking any&#xD;
             vitamins or food supplements one month before study and participation in a previous&#xD;
             investigational drug study within 3 months preceding screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safinaz El Habashy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>eman sakr</last_name>
    <phone>+20206603336</phone>
    <email>niron85@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>11375</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Safinaz ElHabashi</last_name>
      <phone>01116603336</phone>
      <email>safinazelhabashy@med.asu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Nouran yousef</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

